PFE News
Top Research Reports for JPMorgan, ASML & Chevron
JPMorgan, ASML and Chevron stand out in today's research, with earnings strength, AI-driven demand and record production shaping their investment outlooks.
Zacks
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.
Zacks
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsBristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on specialized treatments...
Nasdaq News: Markets
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
Zacks
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.
Zacks
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.
Zacks